A Phase II Study: Efficacy of the Gene Therapy of the MVA E2 Recombinant Virus in the Treatment of Precancerous Lesions (NIC I and NIC II) Associated with Infection of Oncogenic Human Papillomavirus
- 10 June 2002
- journal article
- clinical trial
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 13 (9) , 1127-1140
- https://doi.org/10.1089/104303402753812520
Abstract
No abstract availableThis publication has 40 references indexed in Scilit:
- Human tumor growth is inhibited by a vaccinia virus carrying the E2 gene of bovine papillomavirusCancer, 2000
- Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal modelVaccine, 1996
- Non‐replicating vaccinia vector efficiently expresses bacteriophage T7 RNA polymeraseFEBS Letters, 1995
- B70 antigen is a second ligand for CTLA-4 and CD28Nature, 1993
- Early promoters of genital and cutaneous human papillomaviruses are differentially regulated by the bovine papillomavirus type 1 E2 gene productJournal of General Virology, 1992
- Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7.The Journal of Experimental Medicine, 1991
- Therapeutic Effects of Bovine Enterovirus Infection on Rabbits with Experimentally Induced Adult T Cell LeukaemiaJournal of General Virology, 1991
- Recombinant Vaccinia Virus: Immunization Against Multiple PathogensScience, 1985
- Studies on poxvirus infections in irradiated animalsArchiv für die gesamte Virusforschung, 1980
- MVA-Stufenimpfung gegen PockenDeutsche Medizinische Wochenschrift (1946), 1974